GLP-1 and Dual Agonists: What the Trials Actually Prove

I have a patient — 54, BMI 34, nine months on a GLP-1 agonist, down 17 kilos. Numbers look great. But the DEXA shows she's lost more lean mass than I'd expect. Do I stop the drug?

No. But that DEXA result is exactly the right question. The weight loss from these agents is real, but roughly a quarter to a third of it tends to be lean mass — that's a consistent signal across the major trials.

Is that specific to semaglutide, or tirzepatide too?

Both. Tirzepatide, which hits both the GLP-1 and GIP receptors, produces larger total weight loss in the SURMOUNT trials, but the lean mass fraction lost is similar. More weight lost, more lean mass at risk in absolute terms.

So what do I actually do with that DEXA finding?

Two things with real evidence: resistance training and adequate protein. The STEP trials didn't mandate either, which is part of why the lean mass signal looks the way it does. Adding structured resistance exercise attenuates lean loss — that's trial-level data in this population specifically.

What about the cardiovascular outcomes — that's the reason I'm comfortable with these drugs long-term.

LEADER with liraglutide and SUSTAIN-6 and SELECT with semaglutide are the anchors. SELECT is the one to know — it enrolled people without diabetes, primary endpoint was MACE, and it was positive. That's the first cardiovascular outcomes trial in obesity without a diabetes requirement.

What about tirzepatide for CV outcomes?

Not yet established. SURPASS-CVOT is ongoing. Right now tirzepatide has the glycemic and weight data; the hard cardiovascular endpoint data is semaglutide's.

What do I tell patients about duration? This comes up at every visit.

The STEP 4 trial answers this directly — it randomized people who'd responded to semaglutide to continue or switch to placebo. Two thirds of the lost weight returned within a year of stopping. This isn't a course of antibiotics; it's closer to a chronic disease medication.

That conversation has to happen before the first prescription, not month nine.

Exactly. Frame it at the start: the drug is suppressing appetite centrally and slowing gastric emptying, and both effects reverse when the drug clears. The biology doesn't reset.

Any safety signals I should still be watching actively?

Gastroparesis risk in anyone with pre-existing motility issues — real concern, not theoretical. Pancreatitis signal exists in case reports but hasn't shown up cleanly in the outcomes trials. Medullary thyroid carcinoma is a rodent finding; it's a contraindication based on mechanism, not human outcome data.

And the gastric emptying issue — does that affect other medications she's on?

Yes, and it's underappreciated. Delayed gastric emptying alters absorption kinetics for oral drugs with narrow therapeutic windows — levothyroxine, cyclosporine, some anticonvulsants. Worth a medication review at initiation.

Bottom line — what's the one thing you'd want me to hold onto?

These drugs work, and the cardiovascular data for semaglutide is solid. But the prescription isn't complete without a plan for lean mass preservation and an honest conversation about indefinite duration — before you write it, not after the weight is gone.